Immunocompromised Clinical Trial
Official title:
Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration
Invasive aspergillosis is a serious and often fatal infection in patients who are
neutropenic or have undergone solid organ or stem cell transplantation. However, early
diagnosis of invasive aspergillosis is a challenge. Reiss and Lehmann first described the
value of serum Galactomanna (GM) for diagnosis of invasive pulmonary aspergillosis in 1979.
The availability of the Platelia Aspergillus, a sandwich ELISA that has been approved by FDA
in 2003 for managing patients at risk of invasive aspergillosis because of the early
detection of the GM antigen. In several studies so far the specificity of the serum
galactomannan assay was greater than 85%; however, variable sensitivity from 29~100% was
noted over years. In addition, low values and false-negative results are seen more often in
nonneutropenic and solid organ transplantation patients as opposed to severely
granulocytopenic patients .There are several factors that might explain the reported
difference in the performance of antigen detection, including the biological factors and
epidemiological factors.
In recent years, specimens of other body fluids are increasingly used for detection of
Aspergillus galactomannan antigen, including urine, bronchoalveolar lavage(BAL) fluid,
cerebrospinal fluid and even the tissue specimen. However, the sensitivity and specificity
of the GM detection in various specimens still have considerably variation.
Ultrasound-guided transthoracic aspirate is a safe and useful method for collecting
specimens for accurate bacteriologic diagnosis of lung abscess and obstructive
pneumonitis10. We also reported a study of diagnosis of pulmonary Cryptococosis by
ultrasound guided percutaneous aspiration. We plan to perform a prospective single-center
study to investigate the role of GM in the target organ (lung tissue/fluid) by using
ultrasound-guided fine needle aspirate for early diagnosis invasive aspergillosis compared
with the serum galactomannan.
Invasive aspergillosis is a serious and often fatal infection in patients who are
neutropenic or have undergone solid organ or stem cell transplantation. However, early
diagnosis of invasive aspergillosis is a challenge. Reiss and Lehmann first described the
value of serum Galactomanna (GM) for diagnosis of invasive pulmonary aspergillosis in 1979.
Galactomannan is a water-soluble, polysaccharide cell wall component which is released by
Aspergillus during fungal growth after inhalation of Aspergillus conidia to the lung. The
availability of the Platelia Aspergillus, a sandwich ELISA that has been approved by FDA in
2003 for managing patients at risk of invasive aspergillosis because of the early detection
of the GM antigen. In several studies so far the specificity of the serum galactomannan
assay was greater than 85%; however, variable sensitivity from 29~100% was noted over years.
In addition, low values and false-negative results are seen more often in nonneutropenic and
solid organ transplantation patients as opposed to severely granulocytopenic patients .There
are several factors that might explain the reported difference in the performance of antigen
detection, including the biological factors (non-neutropenic patients, prior exposure to
antifungal agents, encapsulation abscess preventing GM leakage to the circulation, renal
clearance,…etc.) and epidemiological factors (patient population, cut-off value, prevalence
of infection…etc) .
In recent years, specimens of other body fluids are increasingly used for detection of
Aspergillus galactomannan antigen, including urine, bronchoalveolar lavage(BAL) fluid,
cerebrospinal fluid and even the tissue specimen. However, the sensitivity and specificity
of the GM detection in various specimens still have considerably variation.
Ultrasound-guided transthoracic aspirate is a safe and useful method for collecting
specimens for accurate bacteriologic diagnosis of lung abscess and obstructive
pneumonitis10. We also reported a study of diagnosis of pulmonary Cryptococosis by
ultrasound guided percutaneous aspiration. We plan to perform a prospective single-center
study to investigate the role of GM in the target organ (lung tissue/fluid) by using
ultrasound-guided fine needle aspirate for early diagnosis invasive aspergillosis compared
with the serum galactomannan.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05074433 -
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
|
Phase 3 | |
Completed |
NCT01258023 -
Seasonal Flu Vaccine in Adult Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT03808922 -
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
|
Phase 3 | |
Completed |
NCT03262584 -
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
|
||
Recruiting |
NCT03425526 -
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
|
Phase 1 | |
Terminated |
NCT02057289 -
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
|
Phase 1 | |
Active, not recruiting |
NCT03168815 -
Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy
|
N/A | |
Terminated |
NCT01069601 -
H1N1sw Vaccine in Adult Transplant Recipients
|
Phase 2 | |
Withdrawn |
NCT05545319 -
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
|
Phase 2 | |
Completed |
NCT05020145 -
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
|